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Hypertension

Review
Starting Antihypertensive Drug Treatment With
Combination Therapy
Controversies in Hypertension - Con Side of the Argument
Zhen-Yu Zhang , Yu-Ling Yu , Kei Asayama , Tine W. Hansen , Gladys E. Maestre , Jan A. Staessen
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he 2018 European Society of Cardiology/European
Society of Hypertension1 and the 2020 International
Society of Hypertension2 guidelines for the management of hypertension proposed that initial combination
therapy with 2 antihypertensive agents in a single-pill
combination (SPC) is preferred in most patients in need
of blood pressure (BP) lowering treatment and should
replace the long-standing concept of starting treatment
with a single agent, rotating through antihypertensive
drug classes, and next moving towards combining drug
classes. By moving SPCs forward as the initial BP-lowering strategy, the European1 and International2 Societies of
Hypertension Guideline Committees overlooked several
principles in hypertension management: (1) understanding the pathophysiology of hypertension; (2) prioritizing
evidence from randomized clinical trials above observational studies and expert opinion; and (3) giving consideration to the cost-effectiveness of antihypertensive
drug treatment and the sustainability of health care. This
article addresses these points. Sources of information
included (1) guidelines issued by European,1,3,4 American,5–7 International,2,8,9 and British10–12 Expert Committees, published between 19998 and 2020,2 summarized

in Table S1 in the Data Supplement; (2) a PubMed search
ran on May 5, 2020, without limitations with as search
terms in the abstract or title “hypertension” combined
with “fixed combination” OR “hypertension” combined
with “single” and “costs”; (3) the placebo-controlled trials
of antihypertensive drug treatment, as identified from the
reference lists of 5 systematic literature reviews,13–17 of
which 2 were published by the Blood Pressure Lowering
Trialists’ Collaboration14,16; (4) 3 randomized controlled
trials of usual versus intensive BP control18–20; and (5)
the retail costs of antihypertensive drugs on the Belgian
market (https://www.bcfi.be).

TAILORING ANTIHYPERTENSIVE
TREATMENT
In the early 1970s, Laragh’s group coined the terms
low-renin, normal-renin, and high-renin hypertension by
relating plasma renin activity to the daily sodium excretion.21 Under normal conditions, plasma renin activity
increases with sodium restriction but decreases with
higher BP.21 Although an imperfect generalization, lowrenin hypertension is characterized by volume expansion
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CONTROL RATES ON MONOTHERAPY
VERSUS COMBINATION THERAPY
With as objective to estimate the proportion of patients
with hypertension who can be controlled on monotherapy,
we reviewed the placebo-controlled randomized clinical
trials listed in systematic reviews of BP-lowering therapies13–17 as well as the trials of intensive versus usual BP
control.18–20 We extracted control rates on monotherapy
from the trial reports.

Placebo-Controlled Trials
Table 1 lists the placebo-controlled trials from which the
proportion of patients remaining on monotherapy could

be extracted. These trials were published from 198537
until 2008.38 The first Medical Research Council Trial
(age range, 35–64 years)37 and the Perindopril Protection Against Recurrent Stroke Study (age range, not
reported)39 enrolled adults, but all other recruited older
patients,30,31,38,40–43 including exclusively38 or a substantial
proportion of octogenarians.41,42 Considering the patients
randomized to active treatment, at 2 years, from 25.8%38
to 90.0%41,42 remained on a single drug and at 4 years
from 48.0%40 to 87.0%.41,42 In the Hypertension in the
Very Elderly Trial38 and in the Systolic Hypertension in
Europe Trial,30 the study coordinating office emailed or
faxed recommendations for intensification of treatment
to the local investigators, whenever at a visit a patient
was not at goal BP, resulting in a substantially smaller
proportion of patients remaining on monotherapy in
the placebo compared with the active treatment group
(Table 1). In the first Medical Research Council Trial,37
at 4 years of follow-up, 70.0% of patients had attained
the target BP, defined as a diastolic BP of <90 mm Hg.
Thus, a substantial proportion of patients remained on
monotherapy or reached goal BP on a single drug in the
placebo-controlled trials listed in Table 1.

Intensive Versus Usual BP Control
Of the 3 trials18–20 comparing intensive with usual BP
control, 219,20 reported on treatment status by randomization group. In the ACCORD Trial (Action to Control Cardiovascular Risk in Diabetes)19 and in SPRINT (Systolic
Blood Pressure Intervention Trial),20 patients with a systolic BP of 130 mm Hg or higher and an increased cardiovascular risk were randomly assigned to a systolic BP
target of <120 mm Hg (intensive treatment) or a systolic
target of <140 mm Hg (usual treatment). In the type-2
diabetic patients randomized to intensive (N=2174)
and usual (N=2208) BP control in ACCORD,19 after 1
year, the achieved systolic BP averaged 119.3 mm Hg
on intensive treatment and 133.5 mm Hg in the control
group; in SPRINT,20 these levels were 121.4 mm Hg
(N=4683) and 136.2 mm Hg (N=4683), respectively.
In ACCORD (median follow-up, 4.7 years),19 at 1 year,
174 (8.0%) and 265 (28.0%) of patients randomized to
intensive and standard treatment were on monotherapy
and at the last visit 184 (8.0%) and 553 (24.0%); in
SPRINT (median follow-up, 3.3 years),20 these numbers
at last follow-up were 493 (10.5%) and 1455 (31.1%),
respectively.

EVIDENCE SUPPORTING SPCS
The literature on SPCs focuses on efficiency, adherence
(also known as compliance),44 persistence, and safety.
Over time, these notions permeated to several,1–9 but not
all,10–12 guidelines. What is the evidence?
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and its high-renin counterpart by increased peripheral
resistance,22,23 and are indications to start BP-lowering
treatment with a diuretic as opposed to an inhibitor of
the renin-angiotensin system or vasodilator.24 The activity of the renin system decreases with advancing age22
and is lower in Blacks compared with Whites.25–27 These
pathophysiological principles explain why guidelines,
with the exception of the 2018 European1 and the 2020
International2 guidelines recommend to start antihypertensive drug treatment with ACE (angiotensin-converting
enzyme) inhibitors or ARBs below age 55 and with thiazide diuretics (TDs) or dihydropyridine CCBs (calciumchannel blockers) in older patients and in Blacks across
the adult age range. Isolated systolic hypertension, which
in its initial course is not associated with increased
peripheral resistance, but is caused by stiffening of the
large arteries28 is an indication for TDs29 or CCBs.30,31
The 2020 International Society of Hypertension guideline2 supported the use of thiazide-like diuretics, that is,
indapamide and chlorthalidone, rather than regular TDs
(chlorothiazide and hydrochlorothiazide), based on a systematic review of 19 randomized clinical trials involving
112 113 patients.32 The observed benefits were mainly
confined to thiazide-like diuretics rather than TDs with
reductions in the risk of cardiac events (odds ratio, 0.78;
P<0.001), heart failure (odds ratio, 0.57; P<0.001), and
stroke (odds ratio, 0.82; P=0.016).32
ACE inhibitors not only inhibit the generation of active
angiotensin II, but also the inactivation of the vasodilator bradykinin, explaining their higher potency compared
with ARBs and direct renin inhibitors and the recommendation to prescribe ARBs only in ACE inhibitor-intolerant
patients.33,34 The involvement of sympathetic drive and
the renin-angiotensin system in the cardiovascular and
renal complications of hypertension and its comorbidities
clarifies why guidelines1–12 unanimously recommend the
use ACE inhibitors and ARBs in patients with diabetes
or chronic kidney disease, and βBs (beta-blockers),35,36
ACE inhibitors, and ARBs in secondary prevention.

Single Drug vs Single Pill
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Table 1. Patients Remaining on First-Line Drug Treatment in Placebo-Controlled Randomized Clinical Trials

10110

Trial, publication year

Blood pressure, mm Hg

Follow-up, number of patients (%)

Ref

Age, y

Entry

Goal

Y

Drugs

N

HYVET,
2008

38

83.6, ≥80

173.0/90.8
(≥160/<100)

<150/<80

1.8

PLAC

1912

100 (14.2)

IND

1933

196 (25.8)

MRC1,
1985

37

161.3/98.2
(<200/90–109)

NA/<90

PLAC

8654

MRC2,
1992

40

52.0,
35–64

65.7,
65–74

184.7/90.7
(160–209/<115)

4.9

↓13.5/6.5*

BDF

4927

↓9.5/5.5*

PROP

4403

150–160/
NA†‡§

5.8

PLAC

2213

↓13.6/7.0*

HCTZ/AM

1081

↓13.6/7.0*

AT

1102

Year 1

Year 2

Year 3

Year ≥4

… (…)†

… (…)

… (…)

… (…)

… (≈39.9)

… (≈41.9)

… (≈43.9)

… (≈45.9)

… (≈81.9)

… (≈77.4)

… (≈74.3)

… (≈72.3)

… (≈63.1)

… (≈67.1)

… (≈68.1)

… (≈70.1)

… (≈89.9)

… (84.9)

… (≈82.4)

… (≈79.9)

… (≈61.9)

… (66.4)

… (≈67.8)

… (70.4)
… (…)
… (…)
… (62.0)
… (…)
… (48.0)
… (…)
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PROG39
RESS, 2001

65.0, NA

SCOPE,
2004

41,42

76.4,
70–89

164.7/90.4
(160–179/90–99)

>160/>85

STONE,
1996

43

66.4,
60–79

168.5/97.7
(160–219/96–124)

<160/<90

Syst-China,
1998

31

66.4, ≥60

170.5/86.0
(160–219/<95)

>150/NA

Syst-Eur,
1997

30

173.8/85.5
(160–219/<95)

>150/NA

70.3, ≥60

144.0/84.0 (NA)

↓4.9/2.8

3.9

PLAC

1280

… (≈87.0)

PER

1281

… (≈86.0)

3.6

PLAC

845

≈634 (88.0)

≈150 (80.0)

PER

1235

≈998 (90.0)

≈271 (87.0)

2.5

PLAC

815

… (…)

NIF

817

≈531 (65.0)

PLAC

1141

578 (60.4)

348 (42.9)

203 (30.9)

58 (36.0)

NIT

1253

832 (72.3)

584 (62.7)

374 (51.5)

110 (53.7)

PLAC

2297

693 (41.2)

343 (27.8)

178 (19.2)

95 (13.9)

NIT

2398

1037
(59.0)

597 (46.5)

385 (39.3)

216 (30.6)

↓10/NA

3.0

↓20/NA
2.0

↓20/NA

Age: average age at randomization (age eligibility criterion). Blood pressure: the blood pressure data given are the average systolic/diastolic blood pressure at randomization (blood pressure eligibility criteria) and the goal blood pressure (required decrease in blood pressure). In MRC1, nurses doing screening did 2 sets of BP
measurements on separate occasions, but to ensure their diagnostic categorization, the third entry BP was done by a physician. As a result, it took nearly 9 months for
the entry BP to reach its lowest approximately stable level. Mean diastolic BP in women randomized to placebo continued to fall for 5 years. As reported in reference 37,
only a third (N=2285) had no measurements of diastolic BP below 90 mm Hg at any follow-up visit. Follow-up: Data are the number of patients (percentage) remaining
on first-line monotherapy. AT indicates atenolol (50–100 mg/d); BDF, bendrofluazide (10 mg/d); CAND, candesartan (8–16 mg/d); HTCZ/AM, hydrochlorothiazide/
amiloride (25/2.5 mg/d); HYVET, Hypertension in the Very Elderly Trial; IND, indapamide (1.5 mg/d); MRC1, Medical Research Council Trial in Young Adults; MRC2,
Medical Research Council Trial in Older Adults; N, number of patients randomized; NA, not applicable; NIF, nifedipine (20–60 mg/d); NIT, nitrendipine (10–40 mg/d);
PER, perindopril (4 mg/d); PLAC, matching placebo; PROGRESS, Perindopril Protection Against Recurrent Stroke Study; PROP, propranolol (up to 240 mg/d); SCOPE,
Study on Cognition and Prognosis in the Elderly; STONE, Shanghai Trial of Nifedipine in the Elderly; Syst-China, Systolic Hypertension in China Trial; Syst-Eur, Systolic
Hypertension in Europe Trial.; and Y, median or average follow-up on randomized treatment.
*The average placebo-corrected decrease in blood pressure on active treatment.
†An ellipsis indicates that the data could not be extracted from the trial report.
§Number of patients (percentage) reaching goal blood pressure
‡Number of patients (percentage) remaining on monotherapy.

Randomized Clinical Trials
Our extensive literature review revealed only one randomized clinical trial comparing the efficacy and safety
of a SPC with its components.45,46 The COACH Study
(Combination of Olmesartan Medoxomil and Amlodipine Besylate in Controlling High Blood Pressure) was
a double-blind trial, conducted at 172 clinical sites in
the United States.45,46 Patients aged 18 years or older
with a diastolic BP ranging from 95 to 120 mm Hg were
randomized in equal proportions to combination therapy
with olmesartan/amlodipine (daily doses, 10/5, 20/5,
790   March 2021

40/5, 10/10, 20/10, or 40/10 mg) or monotherapy with
olmesartan (10, 20, or 40 mg) or amlodipine (5 or 10
mg). Of 4234 patients, who entered the 2-week washout
phase, 1940 (45.8%) were randomized (women, 45.7%;
mean age, 54.0 years; mean entry BP, 164/102 mm Hg)
and 1689 (87.1%) completed the 8-week trial. Predictably, each treatment modality, compared with placebo,
produced dose-dependent decreases in systolic and diastolic BP and at each dose, combination therapy reduced
BP more and achieved BP control more frequently
(<140/<90 and <130/<90 mm Hg in diabetic patients)
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than the equivalent dose of the single-component drug.
Limitations of the COACH trial were selection of patients
(45.8% of those screened were randomized), the short
washout (2 weeks) and follow-up (8 weeks), the highly
predictable BP results,47 and the post hoc analysis of
patients with isolated systolic hypertension.46
The Simplified Treatment Intervention to Control
Hypertension Study was a cluster-randomized trial,
involving 45 family practices in Ontario, Canada and
compared control rates of hypertension as achieved by
a simplified treatment algorithm (experimental group) or
following the Canadian Hypertension Program guideline
(control group).48 The systolic/diastolic target BP was
<140/<90 mm Hg and <130/<90 mm Hg in diabetic
patients. The simplified treatment algorithm consisted
of the following: (1) initial therapy with a low-dose ACE
inhibitor/TD or ARB/TD SPC; (2) uptitration of the
combination therapy to the highest dose; (3) addition
and subsequent uptitration of a CCB; and (4) addition
of a βB, α-blocker, or spironolactone. The proportion of
patients achieving target BP at 6 months was higher in
the experimental (N=802) than the control (N=1246)
group (64.7% versus 52.7%; P=0.026). At 6 months,
82.8% of patients in the experimental group were on
SPCs and 16.4% in the control group. However, no information on BP control beyond 6 months was provided.48
A third randomized double-blind study evaluated the
efficacy and safety of triple therapy with amlodipine/valsartan/hydrochlorothiazide for moderate or severe hypertension (systolic/diastolic BP, 145/100 mm Hg or higher).49
After a 1-week single-blind placebo run-in, patients were

randomly assigned to valsartan/amlodipine/hydrochlorothiazide 320/10/25 mg, valsartan/hydrochlorothiazide
320/25 mg, valsartan/amlodipine 320/10 mg, or amlodipine/hydrochlorothiazide 10/25 mg with uptitration of
these once daily SPCs from week 1 to week 3. Of the
4285 patients screened, 2271 (53.0%) were randomized
(women, 44.7%; mean age, 53.2 years; mean entry BP,
169.9/106.5 mm Hg) and 2060 (90.7%) completed the
8-week trial. Triple therapy was significantly superior to all
of the dual therapies in reducing BP (P<0.0001).49 Results
were similar across sex, age, and ethnicity strata. The limitations of this study were like those of the COACH trial.45,46
In the double-blind PATHWAY-1 study (Prevention
and Treatment of Hypertension With Algorithm-Based
Therapy Trial),24 of 796 screened patients, 605 (76.0%)
were randomized and 432 (71.4%) completed the
1-year follow-up period. Eligible patients were untreated,
aged 18 to 79 years, and had a self-measured home systolic/diastolic BP of ≥150/≥95 mm Hg. They were randomized to initial monotherapy with losartan 50 to 100
mg/d (N=151) or hydrochlorothiazide 12.5 to 25 mg/d
(N=150), crossing over at 8 weeks (switching to the
alternative monotherapy), or initial combination treatment
with losartan 50 to 100 mg/d plus hydrochlorothiazide
12.5 to 25 mg/d (N=304). In phase 2 (weeks 17–32),
all patients received losartan 100 mg and hydrochlorothiazide 12.5 to 25 mg. In phase 3 (weeks 33–52),
amlodipine with or without doxazosin could be added to
achieve target BP. The primary end point was the change
in the systolic home BP (target systolic/diastolic home
BP >140/>90 mm Hg). The original protocol prespecified the time of the primary end point at the end of phase
2, namely, 32 weeks after randomization, at which time all
patients were receiving the same therapy. The statistical
analysis plan, published before the data lock and unblinding, introduced 2 hierarchical co-primary end points.50
The first was the reduction in the systolic home BP averaged over phases 1 and 2, testing for the superiority of
initial combination therapy over monotherapy. The coprimary end point, to be tested only if the first hypothesis
was confirmed, was the reduction in systolic home BP at
week 32, a time point, when all participants were receiving the same treatment. Comparing initial monotherapy
with initial combination therapy (Figure 1), the systolic/
diastolic reductions in the home BP were 13.3/6.5 versus 21.9/12.1 mm Hg (end of phase 1), 20.1/10.7 versus 19.5/10.6 mm Hg at week 24 (midpoint of phase
2), 23.6/12.7 versus 22.0/11.9 mm Hg at week 32 (end
of phase 2), and 24.5/13.9 versus 23.6/13.4 mm Hg at
week 52 (end of study). By the end of phase 3, over
75% of participants in the initial monotherapy and combination therapy groups had attained the target home BP
with no difference between groups at the end of either
phase 2 or 3.24 Based on the redefinition of the primary
end points,50 the PATHWAY-1 researchers reported the
average BP results combining phases 2 and 3 and all
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Figure 1. Systolic home blood pressure (BP) by
randomization group and follow-up duration.
Data points are means. Vertical bars indicate 95% CI. Patients
were randomized to initial monotherapy with losartan (LOS) 50–100
mg (N=151) or hydrochlorothiazide (HCTZ) 12.5–25 mg (N=150),
crossing over at 8 weeks (switching to the alternative monotherapy),
or initial combination treatment with losartan 50–100 mg plus
hydrochlorothiazide 12.5–25 mg (N=304). In phase 2 (weeks 17–
32), all patients received losartan 100 mg and hydrochlorothiazide
12.5 to 25 mg. In phase 3 (weeks 33–52), amlodipine with or
without doxazosin could be added to achieve target BP. SBP
indicates systolic BP. Reproduced from MacDonald et al24 with
permission. Copyright ©2017, Wiley.
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study periods.24 They concluded that initial combination
therapy achieved target BP in twice as many participants
as initial monotherapy,24 whereas in fact starting from
week 24 (Figure 1), home BP was similar irrespective
of whether antihypertensive treatment was started with
SPC or free SD combination therapy. In the context of
the current debate, a relevant finding of the PATHWAY-1
trial was that the BP reductions induced by losartan and
hydrochlorothiazide were greatest in the top and bottom
plasma renin activity tertiles, respectively,24 an argument
supporting an insightful rather than a simplistic initiation
of antihypertensive drug therapy.

Observational Studies

Downloaded from http://ahajournals.org by on February 11, 2021

A common denominator of all observational studies was
that they had a retrospective design. A meta-analysis
published in 201151 summarized 12 studies published
from 200052 until 2010.53 It compared health care costs,
adherence, and persistence between groups of patients
taking antihypertensive agents as SPCs versus freeequivalent SDs. The mean difference in the annual allcause and hypertension-related health care costs was
$1357 (CI, $778–$1935) lower in favor of SPCs than
free SD combinations. Adherence, measured as the mean
difference in medication possession ratio, was 8% higher
in patients naive to prior antihypertensive drugs and 14%
higher in non-naive SPC patients compared with their
counterparts on free SD combinations. Persistence in
the SPC groups was twice as likely as in the free SD
combination groups (pooled risk ratio, 2.1 [CI, 1.1–4.1]).
The authors hypothesized that improved adherence and
persistence likely contributed to the lower health care
costs in the SPCs groups via improved clinical outcomes.
Of the 12 studies included in the meta-analysis,52–63 2 did
not include a conflict of interest statement,54,56 10 were
directly funded by the pharmaceutical industry,52,53,55,57–63
and 752,56–59,61,63 had one or more co-authors employed by
drug companies having a commercial interest in SPCs.
The early literature was almost unanimous in stating
that SPCs, in comparison with SDs or free combinations
of SDs, were more efficacious in lowering BP, increasing adherence and persistence, and lowering health care
costs. In view of this exceptional consistency, we searched
PubMed for publications with discordant results. We
identified 10 studies,51,64–72 published between 201064
until 2020,73 of which the principal outcome measures,
data sources consulted, the methods applied, and principal limitations are summarized in Table S2. Of the 10
studies,51,64–72 751,64–67,69,70 were directly supported by
SPCs producers, 551,64–67 involved a subcontractor to
these manufacturers, and 551,64,65,67,69 were co-authored
by one or more industry employees. The study by Hong
et al68 stands out, because it was a publication not supported by industry, in which none of the authors reported
a conflict of interest. In this article, free SD combinations
792   March 2021

had average monthly drug costs similar to the respective SPCs, when SPCs were not generically available.68
However, free SD combinations were more expensive
compared with generic SPCs.68
A study published in 2020 without industry support,72
applied the 2014 to 2015 Medical Expenditure Panel
Survey data, to assess the uses and expenses of antihypertensive drugs among American men and nonpregnant
women, aged 18 or older, who had a diagnosis of hypertension. Multiple medications users were patients who
used 2 or more antihypertensive medications each year,
including SPCs or multiple free SD combinations, or who
switched BP-lowering agents within or between classes.
Among 10 971 hypertensive adults, 4759 (44.1%) were
SD users and 6212 (55.9%) were multiple medication
users. The average annual total cost for antihypertensive
medications was $336 per person: $199 for SD users
and $436 for multiple medication users. The average
annual costs for each medication class were estimated
at $438 for ARBs and $49 for TDs. Thus, users of multiple medications, including SPCs, incurred more than
twice the expense than single medication users.72 When
comparing classes of medications, the costs for ARBs
were highest, whereas those for TDs were lowest (Figure 2), a trend still visible in the 2020 retail prizes of antihypertensive drugs on the Belgian market (Table S3).72
Several studies addressed the health-economic
aspects of the use of SPCs versus SDs or free combinations of SDs,65–67,70,73 or triple versus dual SPCs.69 Data
from the MarketScan Database 2006 to 2008 in the
United States showed that SPC patients (N=382 476)
fared better over a 6-month period than their counterparts on free SD combinations (N=197 375).73 The
analyses were adjusted for the baseline characteristics
of the selected patients, a reason why this article73 was
excluded from the 2011 meta-analysis.51 SPC patients
had higher medication possession rates (+11.6%), fewer
all-cause hospitalizations (−23.0%), and emergency
room visits (−13.0%). SPC patients showed greater
reductions in post-therapy initiation in all-cause medical
costs ($208 [CI, −$302 to −$114]), but larger increases
in hypertension-related prescription costs (+$53 [CI,
+$51 to +$55]).73 Similarly, in a study conducted in UK
general-practice, hospitalization costs validated up to
2011 were lower in SPC patients compared with free
SD users (N=9929 versus 18 665; £62 versus £112;
P<0.001), whereas drug costs were higher (£126 versus
£78; P<0.001), resulting in similar mean annual management costs in the 2 groups (£192 versus £192).66
All observational reviewed above (Table S2) had a
retrospective design and were, therefore, vulnerable
to overt and hidden sources of bias, for which analyses did not account. Particularly, most studies had no
information on the severity of hypertension at the time
of initiation or adjustment of BP-lowering treatment,
higher BP being an indication for SPCs or multiple

Hypertension. 2021;77:789–799. DOI: 10.1161/HYPERTENSIONAHA.120.12858

Zhang et al

Single Drug vs Single Pill

Downloaded from http://ahajournals.org by on February 11, 2021

drugs, or on the patients’ health insurance status as
determinant of the out-of-pocket costs and adherence
(Table S2). Data on health behaviors, patients’ lifestyle,
and use of over-the-counter drugs were unavailable.
In several analyses, there was a remarkable imbalance
between SPC and free SD combination users,65–67,73
indicating selection bias in the patients being prescribed SPCs versus free SD combinations or in data
extraction from the claims databases by researchers.
Medication possession rate, although an objective
measure, but only in settings with a closed pharmacy
system,44 is an ambiguous concept. Although there is
moderate association between claims for filled prescriptions and measured drug levels44 or prevention
of adverse health outcomes,74 claims databases do not
ensure that the medication was taken as prescribed.
Moreover, information from claims databases disfavors
free SD drug combinations, because in their publications investigators selected the SD with the worse
adherence,73 or when 2 or more SDs were prescribed,
probabilities of nonadherence were multiplicative, not
additive. Furthermore, the claims data used for the
health-economic analyses were collected for payment
purposes rather than for research. A diagnostic code
on a medical claim is no proof for the presence of disease, because diagnoses might be incorrectly coded
or included as a rule-out criterion rather than as an
actual disease. All reviewed health-economic studies
only accounted for direct health care costs, disregarding patient values,75 and out-of-pocket costs.71 A follow-up duration ranging from 6 months64 to 5 years66
is not representative of the life course of hypertension. No study measured adverse health outcomes in
a prospective manner (Table S2). Transitions between
health states applied in Markov modeling were not
directly measured, but extrapolated,69,70 introducing
arbitrariness in selecting data sources best fitting the
hypothesis to be proven.

Narrative Reviews
Of 7 reviews on the use of SPCs,76–82 published from
200976 until 2019,82 6 were written with direct financial support from SPC manufacturers,77–82 3 included
co-authors employed by these manufacturers,77,79,82 2
involved a for-profit company running the literature
search77 or providing assistance in writing the text,78 and
1 article’s co-author received research support from a
company marketing SPCs.76

TAKE HOME MESSAGES
Table 2 lists the major limitations of the recommended
policy to initiate antihypertensive treatment using SPCs
in most patients.1,2

Weaknesses of Current Guidelines
Lengthy guidelines comprehensible only by hypertension
specialists, lead to therapeutic inertia in primary care and
fall short of their very reason of existence. The 98-page
2018 European recommendations1 go as far as stating
that initial combination therapy is invariably more effective in lowering BP than monotherapy and is, therefore,
indicated in most patients. The reference cited to substantiate this claim was a meta-analysis, not of SPCs
versus SD free combinations, but comparing treatment
strategies consisting of increasing the dose of the firstline antihypertensive agent or adding a second drug
class.47 Two of its authors held patents for a combination pill (polypill) for the prevention of cardiovascular disease.47 To permeate clinical practice, recommendations
must excel in simplicity, allowing summarizing key issues
in a simple mnemonic rule, such as the AB/CD algorithm
in the 2006 British guideline (Figure 3).10 Admittedly, the
position of βBs as first-line treatment remains a matter
of debate, albeit not in the last author’s interpretation of
the literature.36,83 One might argue that SPCs combining
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Figure 2. Estimated average
annual per capita expenses of each
medication class (95% CI), expressed
in US dollars based on the 2014–2015
Medical Expenditure Panel Survey
Notes.
ACEI indicates angiotensin-converting
enzyme inhibitor; ARB, angiotensin
receptor blocker; CCB, calcium-channel
blocker; and TD, thiazide diuretics.
Reproduced from Park et al72 with
permission. Copyright ©2020, Elsevier.
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Issue

Summary of the literature

RCTs

Lack of RCTs comparing the long-term efficiency, adverse
effects, and cost-effectiveness of initiating antihypertensive drug treatment with SPCs as compared with free
combinations of SDs. The scarce RCT evidence currently
available shows that 3 months after initiation of treatment
BP is not better controlled by SPCs than free combinations of SDs. The literature does not support the notion
that early BP control leads to long-term benefit in the
prevention of cardiovascular end points.

Observational
studies

Short-term observational studies, most with retrospective design and short duration (<6 months), are the main
source of information supporting European and International recommendations to start antihypertensive treatment with SPCs. In retrospective observational studies
of SPCs, adverse effects cannot be associated with a
drug class, but are vaguer and more difficult to pick up,
such as fatigue or hypotension, are under-reported.

Sponsors

Manufacturers of SPCs sponsored almost all studies,
explaining bias in choosing data sources informing
health-economic analyses, definitions of nonadherence to SDs, and the complete absence of dissonant
results in the literature.

Health care costs

Use of SPCs increase drug costs, mainly due to the
high retail price of sartans; SPCs do not reduce overall health care costs.

Components of
SPCs

The diuretic in SPCs is overwhelmingly the short-acting hydrochlorothiazide, whereas preference should
be given to the long-acting chlorthalidone. SPCs combining a βB and an ACEI are not guideline-endorsed.

Ease of use

SPCs lack flexibility in combining and dosing individual
drug classes and in spreading dosing of drugs over
the day. Patients with chronic disease value minimizing
side-effects and long-term toxicities over frequency of
dosing and other administration characteristics.

βB indicates β-blockers; ACEI, angiotensin-converting enzyme inhibitors; BP,
blood pressure; RCT, randomized clinical trial; SDs, single drugs; and SPCs, single-pill combinations.

a βB and an ACE inhibitor, as for instance marketed in
Belgium (www.bcfi.be) might allow initiating treatment in
high-renin hypertensive patients in line with pathophysiologic insights, but in line with the older literature84 no
guideline1–12 supports this combination for BP lowering.

Nevertheless, guidelines do support such combination in
secondary prevention.
The pharmaceutical industry is an important motor in
creating therapeutic innovation. To remain profitable, there
is nothing wrong in SPC manufacturers highlighting the
potential benefits of their products. However, a problem
arises when retrospective observational studies52–72 (Table
S2) or systematic51 or narrative76–82 reviews of such studies become the source of information in evidence-based
recommendations. Guidelines should be incremental over
time, meaning that evidence published between successive versions should lead to removing or adjusting previous recommendation or introducing new ones. The British
guidelines10–12 are exemplary in this respect, giving great
weight to new evidence as justification for any change
in treatment advice (Table S1). The 2019 National Institute for Health and Care Excellence recommendation11
stated that there was some limited evidence from a single
study85 that initial dual therapy, compared with placebo,
might reduce cardiovascular complications in people with
hypertension and type-2 diabetes, but the Committee
Members were disappointed that more comprehensive
data were unavailable.11 The Committee discussed the
benefits of optimizing treatment for hypertension early
and agreed that this could substantially improve quality
of life. However, they found that there was not enough
evidence to determine confidently the benefits or harms
of starting antihypertensive treatment with dual therapy.11
The 2018 European guideline1 went on proposing that
the combination of medications targeting multiple mechanisms, such as blocking the renin-angiotensin system and
inducing vasodilatation and diuresis, reduces the heterogeneity of the BP responses to initial treatment and provides
a steeper dose response than is observed with escalating
doses of monotherapy.1 Whereas this might be true during
first 6 months after starting BP-lowering treatment,50,86 this
certainly does not apply to the long-term life course treatment of hypertension (Figure 1). A post hoc analysis of the

Figure 3. Recommendation for
combining blood pressure-lowering
drugs.
First-line drugs with different modes of
action should be combined according to
the AB/CD rule. Reproduced from British
Cardiac Society, British Hypertension
Society, Diabetes UK, HEART UK,
Primary Care Cardiovascular Society, The
Stroke Association10 with permission.
Copyright ©2020, BMJ Publishing Group
Ltd.
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cluster-randomized trial involving 76 primary care practices,71 3592 patients with uncomplicated hypertension
were followed up for 5 years. Physicians were randomized to an out-of-pocket expenditure software module
that provided alerts for out-of-reimbursement costs and
recommended TDs as first-line therapy and control. In the
intervention group, there was a significant increase in the
prescription of TDs in newly treated patients (26.6% versus
19.8%). For patients already treated, older patients were
less likely to be switched to a TD. Translating these findings to the Belgian context (Table S3), starting a patient on
monotherapy with low-dose treatment with chlorthalidone,
bisoprolol, amlodipine, perindopril, valsartan, or olmesartan
entails an annual cost of €19, €38, €44, €72, €87, and
€107, respectively, if the drug with the lowest retail prize
would be prescribed; the corresponding annual expense
for the lowest-cost SPC with valsartan/hydrochlorothiazide,
olmesartan/hydrochlorothiazide, valsartan/amlodipine, and
olmesartan/amlodipine amounts to €85, €107, €128, and
€141. Giving that one-third of the patients started on antihypertensive therapy can be controlled by a SD, the potential savings for the Belgian health insurance are huge, if
patients would no longer be started on dual SPCs.

Rational Use of SPCs
We proposed that starting antihypertensive therapy in
treatment-naive hypertensive patients might be based on
a few simple principles. First, use antihypertensive drugs
with different modes of action in line with the AB/CD
algorithm (Figure 3). Second, use antihypertensive agents
with a long duration of action based on their molecular
structure, so-called forgiving drugs, rather than extendedrelease dosage formulations.94,95 Third, titrate each drug to
the highest dose that does not produce adverse effects.
Fourth, include a thiazide in the drug combination. Finally,
once the right combination has been found by rotating
through and combining drug classes as well as the timing of dosing, stimulate adherence by reducing the pill
load by prescribing SPCs including 2 or 3 antihypertensive agents in adjustable doses. Initiating antihypertensive drug treatment with SDs overcomes the inflexibility
of SPCs in titrating the doses of the SD components and
the timing of their administration, for instance to prevent
nocturnal diuresis or hypotension. In line with the above
proposal, in Japan, only one triple-drug SPC is being
marketed (telmisartan/amlodipine/hydrochlorothiazide
80/5/12.5 mg). It can only be prescribed after 8 weeks
of successful treatment with its components given as dual
SPCs plus one SD or as free 3-drug SD combinations
None of the trials of SPCs had a cardiovascular end point.
In line with the 2019 National Institute for Health and Care
Excellence guideline,11 an important research issue is to
mount outcome-driven randomized clinical trials to delineate
particular subgroups of hypertensive patients who might
benefit from starting dual therapy. Furthermore, compared
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Valsartan Antihypertensive Long-Term Use Evaluation Trial
did not confirm the widely promoted notion in SPC publications that earlier short-term differences in BP lowering
over the long run would reduce cardiovascular end points.87
Furthermore, the European1 and International2 Societies of
Hypertension instructions ignored that the association of
multiple drugs in a single pharmaceutical formulation may
have effects on the pharmacokinetic and pharmacodynamic
properties of each and every individual component and may
lead to undesired interactions between components.88,89
The trials45,46,48–50 and observational studies51–72 reviewed
in this debate article were generally not powered or had
a duration not long enough to highlight serious adverse
effects. As demonstrated by an observational study of
patients aged 50 years or more and reflecting a real-world
setting, use of SPCs was associated with a greater risk of
hypotension than titrated SD free combinations.90 Moreover,
abstraction made of commonly attributable adverse effects,
for example, leg edema or cough respectively on treatment
with CCBs or ACE inhibitors, many drug-induced complaints are vaguer and more difficult to be picked up, such
as for instance fatigue or dizziness and in theory require
rechallenge with the SD components of an SPC to identify
the culprit drug. Fewer pills to be taken daily is a central
concept in the promotion of SPCs,91 but a literature review
with as search terms “preference” AND “patient” AND “pills”
or “SPC”, ran on October 20, 2020, with no limitations, did
not yield any article among the 46 hits that directly translated patient convenience into preference for SPCs in primary or secondary cardiovascular prevention. As a corollary,
treatment-experienced persons living with HIV valued minimizing side-effects and long-term toxicities over dosing and
administration characteristics.92 Preferences varied widely,92
highlighting the need to elicit individual patient preferences,
when decisions about dosing schemes of medications are
made, certainly in the light of the potential adverse events
of SPCs as mentioned before. Finally, the advice to initiate
antihypertensive drug therapy with SPCs also goes against
pathophysiological principles supporting the use of TDs in
low-renin hypertension, Blacks and older patients and the
use vasodilators (ACE inhibitors, ARBs, or CCBs) in highrenin patients or younger individuals (Figure 3).
In an era of epidemiological transition,93 payers, doctors, and patients should join forces to keep health care
sustainable in aging populations. In the placebo-controlled
outcome trials (Table 1),30,31,37–43 a substantial proportion
of hypertensive patients could be controlled on a single
drug. Arguably, the entry and target BPs in these trials were higher than those currently proposed. However,
mutatis mutandis, lower BP levels, at which antihypertensive drug treatment should be initiated,7 would increase the
control rates on monotherapy. BP lowering to <140/90
mm Hg was achieved by monotherapy in about one-third of
patients randomized to standard treatment in ACCORD19
and SPRINT.20 In needy patients, out-of-pocket costs are
a major hurdle in long-term adherence.71 In a Canadian
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with hydrochlorothiazide, chlorthalidone is 1.5 to 2.0 × more
potent, has a substantially longer duration of action (plasma
half-life, 8 versus >24 hours), and is not metabolized but
excreted unchanged in urine, thereby preventing drug-drug
interactions.32,95 Unfortunately, the diuretic in SPCs currently
marketed is overwhelmingly hydrochlorothiazide, an issue
to be addressed by manufacturers (Table 2). Finally, payers
should better inform physicians and patients on the costs of
antihypertensive drugs to reduce health care costs, decrease
out-of-pocket costs as a factor limiting adherence,71 and to
support the sustainability of health care by lower drug costs
and better prevention of the cardiovascular-renal hypertension-associated complications.
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Jan Staessen is an internationally recognized expert known for his independent and integer positions. He and his
coauthors have produced a highly informative, original document against the extensive use of first-line single-pill
combinations.
Still, we feel that it does not detract from our plea in favor of the use of combination therapy as first-line
treatment in most patients with hypertension. Although studies supporting the benefit of this compared to other
strategies have limitations, this is also the case for other treatment strategies used in daily practice. For example,
the arguments in favor of the National Institute for Health and Care Excellence algorithm supported by Staessen and colleagues rest more on clinical expertise and general principles of pharmacology than on rigorously
designed randomized controlled trials.
The recommendation to use dual antihypertensive therapy in most patients with hypertension is more a public
health than a trialist’s perspective.
As indicated by Prof. Staessen, two-thirds of patients with hypertension eventually need ≥2 antihypertensive
drugs to achieve blood pressure control.
We simply think that using single-pill combinations as first-line therapy in those patients is the most effective way
to overcome poor drug adherence and inertia, currently the main barriers to improve blood pressure control worldwide.
Admittedly, this recommendation may benefit the pharma industry. However, it is the responsibility of public
health authorities to negotiate properly the price of single-pill combinations while supporting less expensive,
generic alternatives.
Finally, the gap between Prof. Staessen’s and our conception is less wide than it may appear.
While he focuses on cases in which monotherapy is the preferred approach—basically the same as us, patients
with mild hypertension, particularly older patients with isolated systolic hypertension—we emphasize the big picture in
favor of first-line dual antihypertensive therapy in most patients with hypertension, while mentioning the exceptions.

Hypertension. 2021;77:788–799. DOI: 10.1161/HYPERTENSIONAHA.121.16672

March 2021   799

